MCRB
Seres Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.42
−1.63%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +8.8%
- EBIT
- +23.7%
- EPS
- +69.9%
- Free cash flow
- +15.0%
- Operating cash flow
- +14.5%
Forward estimates
Based on analyst estimates
- Revenue
- +237.5%
- EBITDA
- +79.6%
- EPS
- +57.4%
Three-year CAGR
- Revenue
- —
- EBITDA
- +108.2%
- EBIT
- +22.5%
- Net income
- +103.9%
- EPS
- +103.4%
- Free cash flow
- +100.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026